

MEC APPOINTS MACKIE RESEARCH AS LEAD AGENT FOR PRIVATE PLACEMENT OF PROCEEDS UP TO \$4 MILLION PRE-RTO WITH ALBERT LABS

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet needs.

April 14TH, 2021 - VANCOUVER, BRITISH COLUMBIA, Vancouver, British Columbia – ME Resource Corp. (“**MEC**” or company) is pleased to announce a brokered private placement (the “**Brokered Offering**”) of up to 16,000,000 subscription receipts (the “**Subscription Receipts**”) at a price of \$0.25 per Subscription Receipt for aggregate gross proceeds of up to \$4,000,000, with a 25% over-allotment option or up to an additional 4,000,000 Subscription Receipts, \$1,000,000 in gross proceeds.

The proceeds from the Subscription Receipts will be held in escrow pending the satisfaction of escrow release conditions (the “**Receipt Conditions**”), The company is completing a merger transaction (the “**Merger**”) with MEC Resource Corp. on or before August 31, 2021 unless extended. The proposed transaction On satisfaction of the Receipt Conditions, each Subscription Receipt will automatically convert, for no additional consideration, into one common share of Pubco.

Research Capital Corporation (the “**Lead Agent**”), with a syndicate including Beacon Securities Limited (together, the “**Agents**”) have agreed to act as agents for the Brokered Offering on a best-efforts basis. On closing of the Brokered Offering, the Agents will receive a commission equal to 7.0% of the gross proceeds from the Subscription Receipts sold under the Brokered Offering and a number of broker warrants of the Company (the “**Broker Warrants**”) equal to 7.0% of the number of Subscription Receipts sold under the Brokered Offering. Each Broker Warrant will be exercisable to purchase one common share of the Company at a price of \$0.25 for a period of 24 months following closing.

The securities issued pursuant to the Brokered Offering will be subject to an indefinite hold period until the completion of the Merger.

Completion of the Brokered Offering and the payment of any commission remain subject to the receipt of all necessary regulatory approvals. The proceeds of the private placement will be used for the business of Albert Labs. Read more below.

Please see the news release dated March 5, 2021 for further information about the transaction and the Business of Albert Labs Inc.

ON BEHALF OF THE BOARD OF DIRECTORS

ME RESOURCE CORP.

CHAND JAGPAL, CEO

For further information please
contact:
Tel: +44 7828 008237
Email: chand@albertlabs.com

21 Marylebone High St, Unit 6,
Marylebone, London W1U 4PE
UNITED KINGDOM

6996, Merritt Ave, Burnaby,
BC, V5J 4R6
CANADA



Accelerating patient access to safe and effective psychedelic-assisted therapy.

Cautionary Statement

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate.

The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements.

Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise unless required by the applicable securities laws.